Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.
The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.
Cocrystal Pharma filed a Form 8-K to share a press release about its oral norovirus protease inhibitor CDI-988. Initial progress from a Phase 1b norovirus challenge study will be presented at the 39th International Conference on Antiviral Research (ICAR2026) in Prague.
CDI-988 is described as the first oral antiviral drug candidate under development for prevention and treatment of acute norovirus gastroenteritis and is designed as a pan-viral 3CL protease inhibitor with potential activity against both noroviruses and coronaviruses. The company highlights the lack of approved antiviral therapies or vaccines for norovirus, which causes an estimated 200,000 deaths worldwide each year and significant economic burden, underscoring the potential medical need targeted by this program.
Cocrystal Pharma director-affiliated trust buys additional shares. An entity associated with director and 10% owner Phillip Frost reported purchasing 50,000 shares of Cocrystal Pharma common stock on 02/06/2026 at a weighted average price of $0.9456 per share, with trades ranging from $0.8899 to $0.9880.
After this transaction, Frost Gamma Investments Trust is reported as indirectly holding 1,888,551 shares. Separately, 27,100 shares are held directly, including common stock issuable upon vesting of restricted stock units. Dr. Frost disclaims beneficial ownership of the trust-held and certain other shares except to the extent of any pecuniary interest.
Cocrystal Pharma is granting new non-qualified stock options to its directors, executive officers and a consultant under its 2025 Equity Incentive Plan. The options have a 10-year term, an exercise price equal to the closing price on January 8, 2026, and become effective upon execution of the company’s standard option agreement.
Half of each grant vests on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service. Directors such as Dr. Roger Kornberg and Dr. Philip Frost each received 24,615 options, while James Martin and Sam Lee each received 49,229 options, and a consultant received 40,000 options. The Compensation Committee also approved a $50,000 cash award to Dr. Kornberg for his role as chairman of the Scientific Advisory Board.
Cocrystal Pharma director Roger Kornberg reported a grant of non-qualified stock options on a Form 4. On January 9, 2026 he received stock options to acquire 24,615 shares of common stock at a $1.10 exercise price, expiring on January 9, 2036. The options were granted under Cocrystal Pharma’s 2025 Equity Incentive Plan and approved by the board’s Compensation Committee under Rule 16b-3.
According to the vesting terms, one-half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest and become exercisable in eight equal quarterly installments starting March 31, 2027, as long as Kornberg continues to serve as a director on each vesting date.
Cocrystal Pharma director Richard C. Pfenniger Jr. reported receiving a grant of non-qualified stock options on January 9, 2026. The award covers 16,410 stock options with an exercise price of $1.10 per share, giving him the right to buy Cocrystal Pharma common stock at that price in the future. The options were granted under the company’s 2025 Equity Incentive Plan.
These options vest over time, meaning he earns the right to exercise them gradually. One-half of the grant will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting on March 31, 2027, as long as he continues to serve as a director on each vesting date.
Cocrystal Pharma, Inc. reported that President and Co-CEO Sam Lee received a grant of 49,229 non-qualified stock options on January 9, 2026 under the company’s 2025 Equity Incentive Plan. The options give the right to buy common stock at an exercise price of $1.1 per share and were acquired at no cost.
According to the vesting schedule, one-half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as Lee continues to serve as an officer on each vesting date. All 49,229 derivative securities are reported as directly owned following this grant.
Cocrystal Pharma, Inc. reported that director Fred Hassan received a grant of 16,410 non-qualified stock options on January 9, 2026. The options have an exercise price of $1.10 per share, were granted under the company’s 2025 Equity Incentive Plan, and were approved by the Compensation Committee under Rule 16b-3. One-half of the grant vests and becomes exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, as long as Hassan continues to serve as a director on each vesting date.
Cocrystal Pharma Co-CEO and CFO Martin James Joseph received a grant of 49,229 non-qualified stock options on January 9, 2026. These stock options give him the right to buy up to 49,229 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share, and they expire on January 9, 2036.
Half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as he continues to serve as an officer of the company on each vesting date. The grant was approved by the board’s Compensation Committee under the company’s 2025 Equity Incentive Plan and was reported as a direct beneficial holding.
Cocrystal Pharma, Inc. reported that director and 10% owner Phillip Frost received a grant of stock options. On January 9, 2026, he was awarded 24,615 non-qualified stock options to buy Cocrystal common stock at an exercise price of $1.10 per share, for no upfront cost. These options were approved by the company’s Compensation Committee under the 2025 Equity Incentive Plan.
Half of the options vest and become exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, as long as Frost continues to serve as a director on each vesting date. The filing notes that this report does not include securities owned directly by OPKO Health, Inc., for which Frost disclaims beneficial ownership except for any pecuniary interest.
Cocrystal Pharma director Anthony J. Japour reported a new equity award. On January 9, 2026, he received non-qualified stock options to purchase 16,410 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share under the company’s 2025 Equity Incentive Plan. These options were approved by the Compensation Committee and reported as directly owned.
The options vest over time: one-half becomes exercisable on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, as long as he continues to serve as a director on each vesting date.